“Farmak” company has won two grants from “Horizon 2020” program. Their total amount exceeds 500 thous. EUR. These funds will be spent for the trips of employees to foreign colleagues, company’s website informs.
European Commission launched “Horizon 2020” program for the support of fundamental research in 2014 and allocated 80 bn EUR to it until 2020. This money is being spent to finance projects in three directions: excellent science, industrial leadership and societal challenges. Applications for grants may be submitted by consortia that include scientific institutions and industrial enterprises.
“Farmak” created VAHVISTUS consortium in cooperation with the Institute of Organic Chemistry of the Academy of Sciences of Ukraine, Department of Chemistry at the University of Helsinki (Finland), Institute for Polymers, Composites and Biomaterials in Pozzuoli (Naples, Italy). National Institute of Amazonian Research (INPA, Brazil), Ibn-Tofail University (Kenitra, Morocco) and University of Florida (Gainesville, USA) are also among its partners.
VAHVISTUS submitted grant application on topic “Integrative development of smart drug-vector nanostructures for adaptive delivery to target cells” (direction “excellent science”). According to pharmacists, this preliminary work shall help to treat tropical diseases and provide tools for the development of nanomedicines.
Grant application was selected and received funding from “Horizon 2020” program amounting to 990 thous. EUR.
The share of “Farmak” company in this grant amounted to more than 200 thous. EUR.
Moreover “Farmak” joined ORBIS consortium.
In addition to Kyiv city company it also includes Poznan University (Poland), University of Warsaw (Poland), University of New Jersey (USA), University of Dublin (Ireland), Faculty of Pharmacy of the University of Helsinki (Finland). Zentiva pharmaceutical company and the Irish Applaid Process Consulting became the partners of the consortium.
ORBIS submitted grant application on the topic “Process of pharmaceutical development and problems solving with API solubility and bioavailability” (direction “excellent science”). To implement it “Horizon 2020” allocated 2,268 thous. EUR. The share of “Farmak” was more than 300 thous. EUR.
The company plans to steer money into trips of its employees to other consortium members. According to website of “Farmak” “for the exchange of scientific thought and preliminary works as to the topic of the grant”.
“Participation of “Farmak” in these consortia – opportunity to develop and exchange scientific thought without borders and cross-sectoral barriers through international internships; assistance in development of innovations implementation – embodiment of creative ideas into innovative products, services and processes, as well as the opportunity to be prepared for current and future challenges in the field of health. It is also planned to publish a range of scientific articles and preliminary works on topics of grant programs,” – company’s website quotes Andriy Goy, Technical Director of “Farmak”.